Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists at St. Jude Children's Research Hospital are investigating the inherited genetics of childhood leukemia and how particular gene variations can affect treatment outcomes. The research showed that an inherited variation in the GATA3 gene strongly influences early response to chemotherapy and is linked to relapse in children with acute lymphoblastic leukemia (ALL).
Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in 'teaching' the body's immune T cells to recognize and kill specific cancer cells, and human clinical trials have shown that this approach can successfully eliminate tumors
A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).
Just one in 2,000 bone marrow cells are hematopoietic stem cells (HSC), but these are the source of the ten billion blood cells humans make every day.
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.
Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer.
In order for cancer to form in the human body, normal cells must acquire multiple mutations before they develop toward the disease. It was previously believed that these mutations acted in concert in the progression of cancer.
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.
Rare inherited mutations in the body's master regulator of the DNA repair system – the TP53 gene – can leave people at a higher risk of developing multiple types of cancer over the course of their lives.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.
An adenovirus infection can be potentially life-threatening, especially for children after a stem cell transplant.
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is a group of rare malignancies with overlapping features from myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), that include a variety of diseases depending on their phenotype (hematological and morphological characteristics).
A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.
Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer.
CAR T cell therapy is a new and, in some cases, highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system.
AZoLifeSciences speaks to Professor David J. Rawlings from the Seattle children's hospital about recent developments in engineered T cells for type 1 diabetes.
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells -- a type of immune cell -- with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.